Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

April 20th 2018

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.

Dr. Wolf on the Treatment of High-Risk Patients With Multiple Myeloma

April 20th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.

Fonseca Discusses Integrating Biology and Treatment in Multiple Myeloma

April 19th 2018

Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.

Triplets Reign Supreme in Relapsed/Refractory Myeloma

April 18th 2018

Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.

Dr. Stewart on the Role of Transplant in Multiple Myeloma

April 13th 2018

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Dr. Fonseca on FISH Testing in Patients With Myeloma

April 10th 2018

Rafael Fonseca, MD, hematologist, Mayo Clinic, discusses the use of fluorescence in situ hybridization (FISH) in diagnosing patients with myeloma.

Dr. van Besien on Autologous Stem Cell Transplantation in Hematologic Malignancies

April 4th 2018

Koen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.

Dr. Lonial Discusses Novel Agents in Multiple Myeloma

April 3rd 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

Denosumab Approved in Europe for Myeloma

April 3rd 2018

The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.

Ongoing Advances Transforming Treatment in Myeloma

April 2nd 2018

Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.

Dr. Biran Discusses Doublets Versus Triplets in Myeloma

March 30th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Dr. Landgren on the Use of Triplets Versus Quadruplets in Multiple Myeloma

March 26th 2018

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Ongoing Phase III Trials in Multiple Myeloma

March 21st 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.

Dr. Lonial on Differentiating Patients With Smoldering and Multiple Myeloma

March 13th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses differentiating patients with smoldering myeloma and multiple myeloma.

Dr. Wolf Discusses Treatment Options for Multiple Myeloma

March 9th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with multiple myeloma.

Myeloma Expert Provides Insight on Practice-Changing Data

March 2nd 2018

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Dr. Richter on Toxicities of Treatments for Multiple Myeloma

February 28th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Berdeja Looks Ahead in Multiple Myeloma Treatment

February 26th 2018

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Denosumab Approaches European Approval for Myeloma

February 23rd 2018

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.